Search clinical trials for: Lower dose formulation of HSV vaccine (GSK4108771A)

Total 891 results

GlaxoSmithKline

Terminated

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Herpes Simplex

United States
GlaxoSmithKline

Completed

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Respiratory Syncytial Virus Infections

Taiwan, Spain, United States, Italy, Canada, Panama, Mexico, Poland
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)

Cervical Cancer | HPV | Premalignancy Anogenital Warts
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

Virus Diseases

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

Infections, Respiratory Syncytial Virus

Canada
GlaxoSmithKline

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Respiratory Syncytial Virus Infections

Finland, Spain, United Kingdom, United States, Thailand, Brazil, Canada, Panama, Italy, Colombia, Mexico, Poland, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants

Pneumonia | Pneumococcal Infections | Streptococcus Pneumoniae Infections

Bangladesh
GlaxoSmithKline

Completed

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Respiratory Syncytial Virus Infections

Germany, Estonia, Belgium, France
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Respiratory Syncytial Virus Infections

United States, Australia, Germany, Czechia
GlaxoSmithKline

Completed

To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)

Infections, Rotavirus

Panama
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (VAD00001)

Respiratory Syncytial Virus Infection

Honduras, United States, Chile
GlaxoSmithKline

Completed

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Respiratory Syncytial Virus Infections

United States, Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

Hepatitis B

Germany
Pfizer

Active, not recruiting

A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults

Pneumococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Influenza

United States
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
GlaxoSmithKline

Active, not recruiting

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Hepatitis B, Chronic

Taiwan, Belgium, Thailand, Germany, Spain, Hong Kong, United Kingdom, France, Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Laval University

Completed

Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.

Human Papillomavirus

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
International Vaccine Institute
Bill and Melinda Gates Foundation; SK Bioscience Co., Ltd.

Completed

Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)

Typhoid

Philippines
The University of Hong Kong
Centers for Disease Control and Prevention

Active, not recruiting

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PIVOT)

Influenza, Human

China
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Healthy Volunteers | Respiratory Syncytial Virus Infection | Human Metapneumovirus

United States, Puerto Rico
Sinovac Biotech Co., Ltd

Completed

Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)

Hepatitis B

China
University of Oxford

Completed

A Study of the Safety and Effectiveness of Two New Malaria Vaccines

Malaria

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
Institut Pasteur

Completed

Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine

HIV

Belgium
GlaxoSmithKline

Completed

Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Infections, Rotavirus

United States, Taiwan, Canada, Hong Kong, Turkey
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
The University of Texas Medical Branch, Galveston
Cancer Prevention Research Institute of Texas

Active, not recruiting

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

Efficacy | Human Papilloma Virus | Immunization

United States
Novavax
PATH

Completed

RSV-F Vaccine Dose Ranging Study in Young Women

Respiratory Syncytial Virus (RSV)

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers

Respiratory Disorders

Belgium
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
Sanofi

Completed

Study of Two Investigational Pneumococcal Vaccines in Healthy Adults

Pneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal Pneumonia

Switzerland
Vaxart

Active, not recruiting

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Norovirus Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Pfizer

Active, not recruiting

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons. It Will Be Given Twice Over a Period of Time to Healthy Adults

Clostridoides Difficile Associated Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

Pneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal Pneumonia

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States

3

Subscribe